Table 1 Description of study population
Variablesa | Co-infected (n = 18) | HIV infections alone (n = 18) |
|---|---|---|
Demographic data | ||
Sex, female (%, CI) | 11 (61.1) | 11 (61.1) |
Age (median, IQR) | 36.5 (33.8–41.5) | 35.5 (30.8–45.2) |
Clinical parameters | ||
CD4+ (median/IQR) | 137 (35–197) | 125 (50–182) |
WHO disease stage | ||
2 (n = 3) | 2 (11.1 %) | 1 (5.6 %) |
3 (n = 38) | 15 (83.3 %) | 13 (72.2 %) |
4 (n = 5) | 1 (5.6 %) | 4 (22.2 %) |
ARV combination | ||
d4T + 3TC + NVP (n = 8) | 4 (22.2 %) | 4 (22.2 %) |
d4T + 3TC + EFV (n = 11) | 4 (22.2 %) | 3 (16.7 %) |
CBV + NVP (n = 15) | 5 (27.8 %) | 6 (33.3 %) |
CBV + EFV (n = 12) | 5 (27.8 %) | 5 (27.8 %) |
Hepatitis virus markers | ||
HBeAg | 10 (55.6 %) | – |
Anti-HBe | 8 (44.4 %) | – |
Anti-HBc IgM | 0 (0.0 %) | – |